Minneapolis, Minnesota – (GlobeNewsWire – April 17, 2018) – DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and directors of the Company. The options were issued at $0.56 per share and have a ten-year term.
The options were granted under the Company's Stock Option Plan and are part of the Company's long term incentive/retention plan for employees. The option issuance is subject to the approval of the TSX Venture Exchange.About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941
Source: DiaMedica Therapeutics Inc.